Theranostic/Radionuclide Scan In Bangalore

Theranostic Therapy

What is Theranostics?

Theranostics is the term for a combination of therapeutics and diagnostics (utilizing one radionuclide to picture tumour growths and a second radionuclide to treat cancers by delivering cancer-killing radiation). Essentially, it implies targeting a solitary receptor particle on cancer cells with two different radionuclides (imaging and therapy). This is to accomplish a precise and customized treatment procedure

The Diagnostic Phase of Theranostics

  • Growth cells have a shell, called a membrane; there are certain proteins, for example, the somatostatin receptor (SSTR2) on the cancer cell membrane that can act as a target for cancer drugs.
  • Ga-68 DOTATOC is a radioactive demonstrative medication that targets SSTR2. 
  • Ga-68 DOTATOC is injected into a patient’s vein and goes through the circulatory system to all organs and tissues of the body.
  • If the patient has neuroendocrine cancer with SSTR2 on the growth cell membranes, the Ga-68 DOTATOC will tie to the SSTR2 and the cancer will illuminate on a PET scan

The Therapeutic Phase of Theranostics

When neuroendocrine cancer is analysed utilizing a Ga68-DOTATOC PET scan, the Ga-68 can be replaced with another radionuclide, for example, lutetium-177 (Lu-177) or yttrium-90 (Y-90), that can target and kill growth cells that have SSTR2 on their membranes.

Helpful Y-90-DOTATOC and Lu-177-DOTATATE can both be injected into a patient’s veins and travel to any piece of the body that has SSTR2 proteins. These helpful medications tie to the SSTR2 proteins like a vital lock, permitting the medication to enter the cancer cells and kill them by harming that cell’s DNA. The medication does not impact healthy cells around the cancer that don’t have SSTR2 proteins on their membrane.

Such a procedure permits oncologists to picture treatable cancer tissues all the more, select patients for remedial applications, see precisely where therapeutic agents will be delivered, and screen the capacity of the helpful agent to shrink growth after some time. 

Theranostics give oncologists novel and exceptionally compelling devices to think up precision treatment techniques and foresee the benefits of a specific treatment because of the patient’s extraordinary molecular and genomic profile.

Types of disease we detect through the Radionuclide scan

Top Pet CT Scan

Cancer

Renal ailments

Multiple Myeloma

Skin Cancer

Acute Tubular Necrosis

Pet CT for esophageal Cancer

Lymphedema

Pet CT for esophageal Cancer

Pleural Effusion

Pet CT Scan for Luakemia

Aplastic Anemia

Skin Cancer

Emphysema

Pet CT Scan for Luakemia

Coronary artery disease

Pet CT for Cancer detection

Cervical spondylosis

Radioiodine Therapy

Radioiodine therapy, also known as radioactive iodine therapy or RAI therapy, is a treatment used for hyperthyroidism. It involves ingesting a capsule or liquid containing radioactive iodine-131. The iodine is then absorbed by the thyroid gland to destroy or damage overactive thyroid tissue.

How Does it Work?

Iodine is naturally concentrated in the thyroid gland, which needs iodine to produce thyroid hormones like thyroxine (T4) and triiodothyronine (T3). When radioactive iodine-131 is swallowed, it is absorbed into the bloodstream and transported to the thyroid gland similar to stable iodine. 

Once inside thyroid cells, the radioactive iodine emits small amounts of radiation that slowly damage the cells over time. This radiation damages the DNA of the thyroid cells and makes them unable to function or die. As damaged cells die off, they are replaced by new non-functioning cells. This results in a reduction of overactive thyroid tissue.

What are the Benefits?

Here are some of the key benefits of radioiodine therapy:

  • Highly effective – Radioiodine therapy is very effective at destroying the remaining thyroid tissue after surgery for hyperthyroidism or thyroid cancer. Up to 90% of patients see complete resolution of their overactive thyroid symptoms.
  • Targeted treatment – Radioiodine in the form of iodine-131 is selectively taken up and concentrated in the thyroid gland only. This allows for precise targeting of the thyroid tissue with minimal damage to other organs.
  • Outpatient treatment – Radioiodine is usually administered as an outpatient procedure with no overnight hospital stay needed. Patients can return home the same day after ingesting the iodine capsule/liquid. 
  • Long-lasting results – A single radioiodine treatment is often sufficient to control overactive thyroid levels for many years. Additional treatments are rarely needed once remission is achieved.
  • Non-invasive – Compared to repeated thyroid surgeries, radioiodine therapy provides a non-invasive solution with less surgical risks and scarring. 
  • Cost-effective – The overall cost of a single radioiodine treatment session is lower than multiple surgeries or lifelong thyroid medication.
  • Short recovery – Most patients feel better within weeks of treatment as the thyroid is destroyed. Any short term side effects are usually mild.
  • Minimal side effects – When received from qualified medical professionals, risks of complications or long term effects are very low. 

Radioiodine therapy provides an effective lifelong cure for thyroid problems with high success rates and minimal discomfort.

Lutetium DotaTate Therapy for Neuroendocrine Tumours

What are Neuroendocrine Tumours?

Neuroendocrine tumours (NETs) are a group of cancers that develop from cells of the neuroendocrine system. This system is made up of cells that release hormones in response to signals from the nervous system. NETs can develop in many different organs in the body. Some common sites include the lungs, pancreas, gastrointestinal tract and thyroid.

What is Lutetium Dota Tate therapy?

Lutetium Dota Tate therapy, also known as Lutathera, is a type of radiotherapy used to treat neuroendocrine tumours. It involves injecting a radioactive drug called lutetium Lu 177 dotatate into the bloodstream. Lutetium Lu 177 dotatate selectively binds to somatostatin receptors that are often overexpressed on NET cells. This allows the radioactivity to be delivered directly to the tumour sites. The radiation is then emitted locally to damage the cancerous cells and stop them from growing.

How Does it Work?

Lutetium DotaTate therapy is administered through intravenous injections in an outpatient clinic. The treatment consists of four doses given at 8 week intervals. Before each treatment, somatostatin receptor positron emission tomography (PET) scans are done to identify all tumour sites. This helps the medical team target the radiation dose accurately. Close monitoring of kidney function is also required as the radiation can potentially damage kidneys over time.

What are the Benefits?

  • Targeted therapy: Lu-DOTATATE binds to somatostatin receptors on NET cells, delivering radiation directly to tumours and minimizing damage to healthy tissue.
  • Improved progression-free survival: Studies show significant increases in PFS compared to other treatment options, often doubling or tripling lifespan.
  • Tumour shrinkage and symptom relief: Can shrink tumours and reduce symptoms like pain, fatigue, and hormonal imbalances, leading to improved quality of life.
  • Durable response: The effects of Lu-DOTATATE can sometimes last for years with repeated cycles, offering long-term disease control.
  • Cost-effective: Potential long-term cost savings compared to other treatments due to its prolonged disease control and reduced need for further interventions

Lutetium PSMA Therapy: A New Treatment Option for Prostate Cancer

What is Lutetium PSMA therapy?

radiotherapy treatment for prostate cancer. It involves injecting a radioactive drug called Lutetium-177 into the body. Lutetium-177 attaches to PSMA (prostate-specific membrane antigen) receptors on prostate cancer cells. PSMA is highly expressed on the surface of prostate cancer cells but not normal cells. This allows Lutetium-177 to selectively target and destroy prostate cancer cells while leaving normal cells largely unaffected.

How Does it Work?

In Lutetium PSMA therapy, a PSMA-targeted molecule is linked to the radioactive isotope Lutetium-177. This “theranostic” agent is injected intravenously. It travels through the bloodstream and binds strongly to PSMA receptors on prostate cancer cells. The Lutetium-177 then destroys the cancer cells through a targeted radiation dose over a short range. This helps spare surrounding normal tissues from radiation exposure. Within days, the radioactive material is cleared from the body through the kidneys.

What are the Benefits of Lutetium PSMA therapy

  • Effective tumour control: The therapy directly targets prostate-specific membrane antigen (PSMA), a protein highly expressed in prostate cancer cells. This targeted approach minimizes damage to healthy tissues compared to traditional radiation therapy.
  • Improves symptoms: By controlling tumour growth, the therapy can alleviate pain, fatigue, and other symptoms associated with advanced prostate cancer, leading to improved quality of life.
  • Minimal side effects: Compared to chemotherapy or other aggressive treatments, Lu-PSMA therapy typically has fewer and milder side effects like fatigue, dry mouth, nausea, and temporary changes in blood cell counts.
  • Preserve organ function: The targeted nature of the therapy avoids damaging healthy organs like the kidneys and bladder, which can be affected by other treatments.
  • Promising clinical results: Early studies have shown encouraging results in terms of overall survival and progression-free survival in patients with advanced castration-resistant prostate cancer.

Fapi Therapy: A Promising New Approach

Fapi therapy, also known as fibroblast activation protein (FAP)-targeted radioligand therapy, is a novel cancer treatment showing early promise. It works by targeting FAP, a protein found on cancer-associated fibroblasts. These are cells that help tumors grow by providing nutrients and support.

How Does it Work?

Fapi therapy uses radioactive molecules designed to bind specifically to FAP. Once bound, they deliver radiation directly to the tumor, damaging its DNA and stopping cancer cell growth. By targeting fibroblasts instead of cancer cells directly, it may cause less harm to healthy tissue, reducing side effects.

What are the Benefits?

It precisely delivers radiation only to tumor sites. This specificity could minimize damage elsewhere in the body. It also shows potential for hard-to-treat cancers like pancreatic and some lung cancers. Additionally, some Fapi molecules can be used for both treatment and imaging, allowing doctors to personalize care.